Edition:
United Kingdom

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

15.55USD
15 Dec 2017
Change (% chg)

$0.15 (+0.97%)
Prev Close
$15.40
Open
$15.50
Day's High
$15.75
Day's Low
$15.40
Volume
649,710
Avg. Vol
165,661
52-wk High
$18.35
52-wk Low
$12.25

Latest Key Developments (Source: Significant Developments)

Heron Therapeutics Announces Pricing Of Public Offering Of Common Stock
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF SHARES OF ITS COMMON STOCK​.  Full Article

Heron Therapeutics Announces Public Offering Of Common Stock
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC - INTENDS TO USE PROCEEDS FROM PROPOSED SALE OF ITS SHARES OF COMMON STOCK FOR GENERAL CORPORATE PURPOSES.  Full Article

Heron Therapeutics gets FDA approval for Cinvanti
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Heron Therapeutics Inc :Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv).U.S. Commercial launch of Cinvanti is planned for January 2018​.Remain on-track with htx-011 which we expect to file for FDA review in 2018​.  Full Article

Heron Therapeutics reports qtrly diluted net loss per share $0.77
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress.Qtrly basic and diluted net loss per share $0.77‍​.Heron Therapeutics Inc - ‍net product sales of Sustol for three months ended September 30, 2017 were $8.6 million​.Heron Therapeutics Inc - ‍Heron's cash, cash equivalents and short-term investments were $74.0 million as of September 30, 2017​.Heron Therapeutics Inc - ‍guidance for full-year 2017 net product sales of Sustol remains $25 million to $30 million​.  Full Article

Heron Therapeutics granted FDA fast track designation for HTX-011
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours.Heron Therapeutics Inc - ‍Phase 3 studies for HTX-011 ongoing; NDA filing planned for 2018​.Heron Therapeutics - ‍expect to report top-line results from pivotal phase 3 studies in first half of 2018 and file for FDA review in second half of 2018​.  Full Article

Heron Therapeutics says three members of management team will be leaving the company
Friday, 30 Sep 2016 

Heron Therapeutics Inc : Says three members of management team will be leaving Heron Therapeutics, Inc - SEC filing . Says resignation of Mr. Drazba will be effective as of March 31, 2017 .Accepted resignations of Neil Clendeninn, chief medical officer and Brian Drazba, chief financial officer.  Full Article

Heron Therapeutics reports Q2 2016 financial results and recent corporate progress
Monday, 8 Aug 2016 

Heron Therapeutics Inc : Heron Therapeutics reports second quarter 2016 financial results and recent corporate progress .Heron Therapeutics inc qtrly loss per share $1.17.  Full Article

Heron Therapeutics signs loan agreement for up to $100 mln
Tuesday, 2 Aug 2016 

Heron Therapeutics Inc : Heron therapeutics enters into loan agreement for up to $100 million . Entered into an agreement with Tang Capital Partners, lp whereby tang capital will lend company up to $100 million . Loan will have a two-year term and bear interest of 8% per annum. . First close of $50 million is expected to occur within five business days .Second close of an additional $50 million is subject to achievement of a corporate milestone.  Full Article

Heron Therapeutics files for potential mixed shelf, size not disclosed - SEC Filing
Friday, 29 Jul 2016 

Heron Therapeutics Inc :Files for potential mixed shelf, size not disclosed - SEC Filing.  Full Article

Heron Therapeutics Provides Update on FDA Review of SUSTOL((reg))NDA
Monday, 18 Apr 2016 

Heron Therapeutics:Says the U.S. Food and Drug Administration (FDA) has provided the Co with an update on its review of the New Drug Application (NDA) for SUSTOL((reg))(granisetron) Injection, extended release.The FDA has indicated that there are no substantive deficiencies in the NDA and has begun labeling discussions with the Company.  Full Article